A Phase 2 interventional study of Sulthiame in Obstructive Sleep Apnea, sponsored by Desitin Arzneimittel GmbH. Completed at 1 site in Belgium. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by Desitin Arzneimittel GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Sleep Apnea, Obstructive with a site in Belgium — 22 open to participants now, 26 under way, none of them phase 3. Sleep Apnea, Obstructive · Belgium.
Among the 80 studies in Sleep Apnea, Obstructive with a site in Belgium, this one is the 2nd largest by enrollment of the 42 interventional ones that give a count, is one of 9 that started in 2021, is the only one in phase 2, and was the 52nd registered.
2,244 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →22 of the 80 studies in Sleep Apnea, Obstructive with a site in Belgium are open now. Recruiting first, the newest first:
University Hospital, Antwerp · Sites in Belgium
Ages 18+
University Hospital, Antwerp · Sites in Belgium
Ages 18+
Université Catholique de Louvain · Sites in Belgium
Ages 4–17
Inspire Medical Systems, Inc. · Sites in Belgium, Austria, France and 4 more countries
Ages 18+
Sint Dimpna Ziekenhuis Geel · Sites in Belgium
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 313 Sleep Apnea, Obstructive studies recruiting now, 147 (47%) set no upper age limit and 123 (39%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 298 is above the median of 52 across 1,475 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 41 across the 42 interventional studies, 141 across the 38 observational. Of the 44 that completed or were terminated, 6 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 80 have an industry lead sponsor. The 10 most frequent:
Desitin Arzneimittel GmbH is the lead sponsor of 13 studies on the registry; none are open to participants now.
Desitin Arzneimittel GmbH has 1 study filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
4 of the studies in Sleep Apnea, Obstructive with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05315752Centre Hospitalier Universitaire Saint PierreChanges in Body Fat and Morphologic Characteristics Associated With OSA Resolution After Bariatric Surgery | 2026-12-31 |
| NCT06915077University Hospital, AntwerpPersonalised Treatment for OSA | 2027-01 |
| NCT07910461CHR Sambre et Meuse Site MeuseOrthognathic Surgery and Obstructive Sleep Apnea Assessed by Mandibular Jaw Movement Monitoring (SUNRISE-ORTHO) | 2027-06-15 |
| NCT06792045Université Catholique de LouvainPrediction of Tongue Base Obstruction During Sleep | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 80 studies in Sleep Apnea, Obstructive with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
multi-center, randomized, double-blind, placebo-controlled, dose-finding, 4-arm, parallel assignment study to evaluate the efficacy of three different doses of sulthiame (STM) compared to placebo on sleep apnea activity in adult patients with obstructive sleep apnea.
Primary objective: To evaluate the efficacy of 3 different doses of Sulthiame (STM) compared to placebo on sleep apnea activity in adult patients with moderate to severe obstructive sleep apnea (OSA) after at least 12 weeks of treatment at target dose
Secondary objectives: To evaluate the effect of 3 different doses of STM after at least 12 weeks of treatment at target dose in patients with moderate to severe OSA on apnea/hypopnea events, hypoxic burden, sleep quality, daytime sleepiness, patient's perception of symptoms and well-being, comorbidity-related outcomes and safety and tolerability of STM
Exploratory objective: To evaluate potential predictive biomarker (eg, blood gas analysis parameters or additional polysomnography [PSG] variables) with regard to efficacy
Key Inclusion Criteria:
Key Exclusion Criteria:
Other sleep disorder including periodic limb movement disorder, restless leg syndrome, periodic limb movement arousal index (PLMAI) of >15*, insomnia, parasomnia or narcolepsy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sulthiame film-coated tablets 100 mg once daily 15 weeks
Drug: Sulthiame
Sulthiame film-coated tablets 200 mg once daily 15 weeks
Drug: Sulthiame
Sulthiame film-coated tablets 300 mg once daily 15 weeks
Drug: Sulthiame
Placebo film-coated tablets once daily 15 weeks
Drug: Sulthiame
oral
Also known as: Ospolot
Relative change in apnea-hypopnea index (AHI) from baseline to Week 15 (at least 12 weeks of treatment at target dose) measured by PSG
change in apnea-hypopnea index (AHI)
Time frame: from baseline to week 15
Number and percentage of patients reporting adverse events, treatment-emergent adverse events (TEAEs) , serious TEAEs, related TEAEs, related serious TEAEs, TEAEs leading to discontinuation of study drug.
Two-sided 95% confidence intervals for the difference in patient incidence between each sulthiame treatment group and placebo.
Time frame: from baseline to week 15
Ran from Nov 2021 to primary completion in Aug 2023, 20 months.
Of 47 phase 2 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sulthiame
Desitin Arzneimittel GmbH